Smith & Nephew: are shares in this FTSE 100 company a buy?
More on: Image source: Getty Images.
The medical device industry – often seen as the poor relation of the pharmaceuticals and healthcare space – suffered in 2020. Elective routine surgical procedures took a back seat for most of last year, but now that the Covid-19 vaccine programme is gaining pace, things are looking up for one FTSE 100 company.
The share price for
Smith & Nephew(LSE: SN) has grown 15% over the last six weeks alone, and still has some way to go, if its pre-pandemic stock valuation is anything to go by. This, together with the fact that the company has never yet failed to pay out a dividend since it was first listed back in the 1930s, leads me to give it serious consideration as an addition to my investment portfolio.
Joe Delgado, chief financial officer of Preceptis Medical, had a personal reason for leaving a good job at UnitedHealth Group a few years ago.
His daughter, Vivian, now 5 years old, benefited from a tube implanted in her ears using a Preceptis Hummingbird device. The procedure was done in a doctor s office. No hospital operating room or anesthesia was needed. That made it far less costly than the standard procedure, which can run up to $5,000, and less worrying. Vivian previously had a set of tubes inserted in the traditional manner. I ll never forget the moment we handed our 9-month-old baby to the nurse to be put under general anesthesia, Delgado said. It was very traumatic for me and my wife. After her tubes fell out in four months, my wife and I both wanted an alternative.
Why I think FTSE 100 medical tech stock Smith & Nephew looks a good investment fool.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.co.uk Daily Mail and Mail on Sunday newspapers.